Latest News
Organizational flips help B-I deal with complexity challenges, says expert
Organizational flips help B-I deal with complexity challenges, says expert
Through changing the traditional organizational structure to include all functions in one team, the setup can support complexities in manufacturing projects, says Boehringer Ingelheim.
Deal-Making
Singapore’s SCG Cell Therapy and A*STAR, an official Singapore investor, will team up to build new joint laboratory research labs for cellular immunotherapies.
Alvotech will produce its interchangeable biosimilar to Humira (adalimumab) under a private label for Quallent Pharmaceuticals.
Facilities & Capacity
As part of its restructuring plan, Emergent BioSolutions will cut around 300 jobs across all areas of its business and shut down its facilities in Bayview, Baltimore and Rockville, Maryland.
Asimov has launched a stable cell line development service, which it claims is 10 times more efficient in lentiviral production.
Global Markets
Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Regulations
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Therapeutic Class
Singapore’s SCG Cell Therapy and A*STAR, an official Singapore investor, will team up to build new joint laboratory research labs for cellular immunotherapies.
Contract development and manufacturing organization (CDMO) Oxford Biomedica has launched its One OXB strategy in an effort to align its global footprint.
Upstream & Downstream Processing
Repligen says it is looking at new modalities and its filtration franchise to drive momentum following a mixed first quarter 2024.
Through changing the traditional organizational structure to include all functions in one team, the setup can support complexities in manufacturing projects, says Boehringer Ingelheim.